<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084444</url>
  </required_header>
  <id_info>
    <org_study_id>T8-201</org_study_id>
    <nct_id>NCT04084444</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients</brief_title>
  <official_title>To Evaluate the Efficacy and Safety of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients: A Multicenter, Randomized, Double-blind, Dose-exploration, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the efficacy and safety of taking T8 once daily on treating chronic abnormal
           immune activation in AIDS patients.

        2. To explore dose-effect relationships of taking T8 once dailyon treating chronic abnormal
           immune activation in AIDS patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ T lymphocyte count</measure>
    <time_frame>48 week</time_frame>
    <description>The changes of CD4+ T lymphocyte count before treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects whose CD4+ T lymphocyte count increased ≥50 /μL</measure>
    <time_frame>48 week</time_frame>
    <description>The percentage of subjects whose CD4+ T lymphocyte count increased ≥50 /μL before treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The changes of inflammatory cytokines</measure>
    <time_frame>48 week</time_frame>
    <description>The quantitative changes of inflammatory cytokines（IP-10、hsCRP、IL-6）from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+/CD8+T lymphocyte ratio</measure>
    <time_frame>24 week and 48 week</time_frame>
    <description>The changes of CD4+/CD8+T lymphocyte ratio before treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T lymphocyte count increased by ≥20%</measure>
    <time_frame>24 week and 48 week</time_frame>
    <description>CD4+ T lymphocyte count increased by ≥20% compared with that before treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T lymphocyte count ≥ 200 /μL</measure>
    <time_frame>24 week and 48 week</time_frame>
    <description>The proportion of subjects with CD4+ T lymphocyte count &lt; 200 /μL before treatment and ≥200 /μL after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE and SAE</measure>
    <time_frame>24 week and 48 week</time_frame>
    <description>The incidence of AE and SAE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CD8+ T lymphocyte activation</measure>
    <time_frame>24 week and 48 week</time_frame>
    <description>The changes of CD8+ T lymphocyte activation (CD8+CD38+%，CD8+HLA-DR+%) compared with that before treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Abnormal Immune Activation</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>T8 tablet 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T8 tablet 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral T8 tablet with HARRT, 1mg, once daily for 48 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo with HARRT, once daily for 48 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T8 tablet 0.5mg</intervention_name>
    <description>Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.</description>
    <arm_group_label>T8 tablet 0.5mg</arm_group_label>
    <other_name>Leiteng Shu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T8 tablet 1mg</intervention_name>
    <description>Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.</description>
    <arm_group_label>T8 tablet 1mg</arm_group_label>
    <other_name>Leiteng Shu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blank control.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Male or female whose age is 18-65.

          -  2.Body mass index (BMI) ≥18 (kg/m2); Male weight ≥50kg, female weight ≥45kg.

          -  3.Chronic HIV infections with treated by HAART over 4 years.

          -  4.Subjects must meet the criteria for sustained virology inhibition: maintain HIV-1
             RNA below the lower limit of detection (50 copies /mL) over 3.5 years, except for
             transient venereal; Subjects should provide at least 2 test results of HIV-1 RNA lower
             than the lower limit of detection, and the earliest detection time is earlier than 3.5
             years.

        HIV-1 RNA should be less than 50 copies /mL at subject screening.

          -  5.Subjects must meet the criteria for immunoreestablishment insufficiency: CD4+ T
             lymphocyte count &lt; 350 /μL in 1 year before screening; Test results of CD4+ T
             lymphocyte count &lt; 350 /μL should be provided at least 2 times, and the interval
             between these two tests should be ≥3 months (the results of screening period will be
             accepted).

        When subjects are screened for enrollment, CD4+ T lymphocyte count should be &lt; 350 /μL.

          -  6.No birth planning during the trial and within 1 year after the trial; subjects must
             agree to use effective non-drug contraception during the trial.

          -  7.Understand and sign informed consent voluntarily.

        Exclusion Criteria:

          -  1.Have a history of allergic to tripterygium wilfordii drugs; be allergic
             constitution.

          -  2.Pregnant or lactating women.

          -  3.Those who had received immunosuppressant or other immunomodulator (e.g., thymosin)
             or systemic cytotoxic drug therapy within 6 months befor screening.

          -  4.Diagnosed with other types of immunodeficiency.

          -  5.Active opportunistic infection.

          -  6.The titers of antinuclear antibody is higher than 1:160.

          -  7.HBsAg was (+), and/or anti-HCV and HCV-RNA were (+)

          -  8.Who have a history of vaccination within 6 weeks or plan to be vaccinated in the
             next year.

          -  9.Diagnosed with malignant tumors.

          -  10.the laboratory test meets any of the following conditions:

               -  hemoglobin (HGB) &lt; 100g/L;

               -  white blood cell (WBC) count &lt; 3.5×10^9/L or neutrophil count (NEUT) &lt;
                  1.5×10^9/L;

               -  platelet count (PLT) &lt; 80×10^9/ L;

               -  blood creatinine (Cr)＞1.5 times normal upper limit (ULN);

               -  alanine aminotransferase (ALT) &gt; double normal upper limit (ULN);

               -  aspartate transaminase (AST) &gt; double normal upper limit (ULN);

               -  alkaline phosphatase (ALP) &gt; double normal upper limit (ULN);

               -  total bilirubin (TBIL) &gt; 1.5 times normal upper limit (ULN).

          -  11.Diagnosed with Severe gastrointestinal disease.

          -  12.Diagnosed with severe cardiovascular disease (including unstable angina pectoris,
             severe arrhythmia)

          -  13.Diagnosed with Severe cerebrovascular disease

          -  14.Having a history of alcohol and drug abuse.

          -  15.Participate in other clinical trials within 3 months before screening.

          -  16.Any other conditions that the researcher considers not to be able to participate in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisheng Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhen Tan, Master</last_name>
    <phone>+86-020-63730908</phone>
    <phone_ext>3009</phone_ext>
    <email>tanz@sphchina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taisheng Li, PhD</last_name>
      <phone>+86-010-69155086</phone>
      <email>litsh@236.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Dita Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongxin Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing You An Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongxia Wei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Biao Zhu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic abnormal immune activation</keyword>
  <keyword>AIDS</keyword>
  <keyword>T8</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

